Acta Scientific Microbiology (ASMI) (ISSN: 2581-3226)

Short Communication Volume 3 Issue 2

Biological Control of Aedes Egypti and Dengue Virus with Bacteria Wolbachia

Khalid Al-ghamdy1 and Ishtiaq Qadri2

1Department of Biological Sciences, Faculty of Science, King Abdul-Aziz University, Jeddah, KSA

2Head Virology, Department of Biological Sciences, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia

*Corresponding Author: Ishtiaq Qadri, Head Virology, Department of Biological Sciences, Faculty of Medicine, King Abdul Aziz University, Jeddah, Saudi Arabia.

Received: December 12, 2019; Published: January 06, 2020


  Dengue virus is a mosquito borne flavivirus and cusses 50 million infection each year. The spread of the virus through the female mosquito Aedes egypti or Aedes albopictus is very fast and containment strategies are constantly explored to stop the infection into human. Due to topographical dissemination of these mosquito vectors, over 2 billion individuals are at risk of contracting the infection and dengue hemorrhage fever (DHF). The disease in now epidemic to over 100 countries and 4 different serotypes have been reported from the insects and human. So far the containment and vaccine strategies are not effective to control the mosquito and spread of virus. Several countries have attempted to develop vaccines but are largely in clinical phases trials and result indict that such vaccines are not strong immunogenic against all Dengue serotypes. A live attenuated tetravalent chimeric vaccine Dengvaxia, is commercially available in limited high risk areas of Thailand and Brazil. The plasmid for vaccine was constructed by replacing the yellow fever attenuated 17D strain with that of the pre-membrane (PreM and Envelope (E) region of four dengue serotypes Unpublished reports indicate from phase 3 clinical trials with 31,000 children of 2 - 14 years, that efficacy with Dengvaxia was 50 to 60%. An inactivated tetravalent vaccine (TDEN PIV) is jointly developed by GSK and the Walter Reed Army Institute which is based on a synergistic (boost) concept. In this scheme the immunogenicity, of primary vaccine is enhanced with another serotype. Pharmaceutical giant Merck is in the process of developing a subunit vaccine based on fruit fly D. melanogaster Schneider cells. All these efforts are in the initial stages of development. Therefore, multiple approaches are obligatory for mosquito eradication, such as biological control, insecticide and new antivirals strategies to inhibit virus translation and replication.

Keywords: Sixth Nerve Palsy; Chikungunya Virus Infection





Citation: Khalid Al-ghamdy and Ishtiaq Qadri. “Biological Control of Aedes Egypti and Dengue Virus with Bacteria Wolbachia". Acta Scientific Microbiology 3.2 (2020): 22.


Acceptance rate30%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is May 30, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US